TABLE 4.
Most frequent unknown drug-ADR pairs.
| System organ Class/ADR(n) | Drugs involved (n) | Covid drugs involved (n) |
|---|---|---|
| Skin and subcutaneous tissue disorders (34; 11.5%) a | ||
| Pemphigoid (7) | repaglinide (2); risperidone (1); rota virus, live attenuated (1); diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B (1); pneumococcus, purified polysaccharides antigen conjugated (1); vortioxetine (1); meningococcus B, multicomponent vaccine (1) | |
| Cutaneous vasculitis (6) | metamizol sodium (2); cefuroxime (1); colchicine (1); dexketoprofen (1) | COVID-19 Vaccine (chadox1-S) (1) |
| Urticaria (3) | procarbazine (2); nomegestrol/estradiol (1) | |
| Hepatobiliary disorders (28; 9.5%) | ||
| Hepatic cytolysis (6) | bevacizumab (1); dexamethasone (1); lidocaine (1); sugammadex (1); ticagrelor (1); vincristine (1) | |
| Mixed liver injury (4) | clonidine (1); metamizole sodium (1); teriflunomide (1); ticagrelor (1) | |
| Hepatitis cholestatic (3) | canagloflizone (1); dapagliflozine (1); ticagrelor (1) | |
| Hypertransaminasemia (3) | vincristine (3) | |
| Pregnancy, puerperium and perinatal condition (17; 5.8%) a | ||
| Fetal growth restriction (6) | ondansetron (2); metoclopramide (1); diphtheria-pertussis-poliomyelitis-tetanus (1); ranitidine (1); influenza, inactivated, split virus or surface antigen (1) | |
| Fetal death (5) | clonazepam (1); haloperidol (1); lamotrigine (1); sertraline (1); valproic acid (1) | |
| Premature rupture of membranes (4) | azathioprine (1); escitalopram (1); infliximab (1); olanzapine (1) | |
| Vascular disorders (16; 5.4%) a | ||
| Distributive shock (5) | bisoprolol (1); enalapril (1); furosemide (1); hydrochlorothiazide (1); tocilizumab (1) | |
| Deep vein thrombosis (3) | COVID-19 Vaccine (tozinameran) (1); COVID-19 Vaccine (chadox1-S) (1); COVID-19 Vaccine (AD26) (1) | |
| General disorders and administration site conditions (13; 4.4%) a | ||
| Sudden death (6) | Adalimumab (1) | hydroxychloroquine or hydroxychloroquine with others drugs (4); COVID-19 Vaccine (tozinameran) (1) |
| Blood and lymphatic system disorders (17; 5.8%) a | ||
| Disseminated intravascular coagulation (3) | dabrafenib (1); tigecicline (1); trametinib (1) | |
| Pancytopenia (3) | doxazozin (1); natalizumab (1) | COVID-19 Vaccine (elasomeran) (1) |
| Nervous system disorders (27; 9.2%) a | ||
| Reversible posterior encephalopathy syndrome (3) | lenalidomide (1); immunoglobulins, normal human, for intravascular administration (1) | Methylprednisolone (1) |
| Guillain-Barré syndrome (3) | oxaliplati (1); raltitrexed (1); hepatitis A, inactivated, whole virus (1) | |
| Infections and infestation (12; 4.1%) a | ||
| Herpes zoster (4) | botulinum toxin (1) | COVID-19 Vaccine (tozinameran) (2); COVID-19 Vaccine (chadox1-S) (1) |
| Gastrointestinal disorders (16; 5.4%) a | ||
| Ascites (3) | lecarnidipine (2); oseltamivir (1) | |
| Respiratory, thoracic and mediastinal disorders (14; 4.7%) | ||
| Pulmonary embolism (3) | lamivudine/abacavir/dolutegravir (1) | COVID-19 Vaccine (tozinameran) (1); COVID-19 Vaccine (chadox1-S) (1) |
| Renal and urinary disorders (5; 1.7%) a | ||
| Acute kidney injury (3) | deoxycholic acid (1); glicazide (1); methylprednisolone (1) | |
| Cardiac disorders (28; 9.5%) a | ||
| Cardiac failure (3) | sirolimus (1) | COVID-19 Vaccine (tozinameran) (2) |
a
See Supplementary Table S3 with all Unknown drug-ADR pairs with an ADR ≤ 2.